NASDAQ · Healthcare · Biotechnology
Prelude Therapeutics Incorporated
PRLD
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. CEO Krishna Vaddi · Market cap $260.2M.
$4.67
+0.03 · +0.65%
52w hi $5.5452w lo $0.75
Off 52w high 15.2%
75
STRONG
Current InsiderScore
Corp · 90d
4
4 buys · 0 sales
Cong · 90d
0
0 buys · 0 sales
Signals ≥ 60 · 12mo
4
2 strong · 2 notable
Analyst consensus
Strong Buy
Avg PT $6.25
Section 01
Recent Form 4 filings
4 filings on file
| Date | Insider | Role | Action | Shares | Price | Value | Score |
|---|---|---|---|---|---|---|---|
| Apr 21 | David P Bonita | Buy | 1,689,189 | $4.44 | +$7.50M | 71 | |
| Apr 21 | ORBIMED ADVISORS LLC | Buy | 1,689,189 | $4.44 | +$7.50M | 71 | |
| Apr 21 | David P Bonita | Buy | 1,126,126 | $4.44 | +$5.00M | 75 | |
| Apr 21 | ORBIMED ADVISORS LLC | Buy | 1,126,126 | $4.44 | +$5.00M | 75 |
Section 02
Recent STOCK Act disclosures
No disclosures yet
No STOCK Act disclosures on record for this ticker.
Section 03
InsiderScore history
Rolling 12 months · peak score per month
JunJulAugSepOctNovDecJanFebMarAprMay